Denmark · Delayed Price · Currency is DKK Embla Medical Statistics
Total Valuation
Embla Medical has a market cap or net worth of DKK 11.42 billion. The enterprise value is 14.43 billion.
| Market Cap | 11.42B |
| Enterprise Value | 14.43B |
Important Dates
The last earnings date was Tuesday, April 28, 2026.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Embla Medical has 426.87 million shares outstanding. The number of shares has decreased by -0.42% in one year.
| Current Share Class | 426.87M |
| Shares Outstanding | 426.87M |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | +1.06% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 72.73% |
| Float | 157.53M |
Valuation Ratios
The trailing PE ratio is 20.47 and the forward PE ratio is 18.45. Embla Medical's PEG ratio is 1.11.
| PE Ratio | 20.47 |
| Forward PE | 18.45 |
| PS Ratio | 1.84 |
| PB Ratio | 1.95 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.50 |
| P/OCF Ratio | 13.76 |
| PEG Ratio | 1.11 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.84, with an EV/FCF ratio of 20.85.
| EV / Earnings | 26.00 |
| EV / Sales | 2.32 |
| EV / EBITDA | 11.84 |
| EV / EBIT | 16.90 |
| EV / FCF | 20.85 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.21 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 3.04 |
| Debt / FCF | 5.18 |
| Interest Coverage | 6.56 |
Financial Efficiency
Return on equity (ROE) is 10.10% and return on invested capital (ROIC) is 7.20%.
| Return on Equity (ROE) | 10.10% |
| Return on Assets (ROA) | 4.76% |
| Return on Invested Capital (ROIC) | 7.20% |
| Return on Capital Employed (ROCE) | 9.39% |
| Weighted Average Cost of Capital (WACC) | 5.75% |
| Revenue Per Employee | 1.48M |
| Profits Per Employee | 132,323 |
| Employee Count | 4,195 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, Embla Medical has paid 162.79 million in taxes.
| Income Tax | 162.79M |
| Effective Tax Rate | 22.58% |
Stock Price Statistics
The stock price has decreased by -10.86% in the last 52 weeks. The beta is 0.45, so Embla Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -10.86% |
| 50-Day Moving Average | 28.12 |
| 200-Day Moving Average | 31.40 |
| Relative Strength Index (RSI) | 41.47 |
| Average Volume (20 Days) | 275,308 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Embla Medical had revenue of DKK 6.21 billion and earned 555.09 million in profits. Earnings per share was 1.31.
| Revenue | 6.21B |
| Gross Profit | 3.85B |
| Operating Income | 813.35M |
| Pretax Income | 721.05M |
| Net Income | 555.09M |
| EBITDA | 988.74M |
| EBIT | 813.35M |
| Earnings Per Share (EPS) | 1.31 |
Balance Sheet
The company has 607.11 million in cash and 3.58 billion in debt, with a net cash position of -2.98 billion or -6.97 per share.
| Cash & Cash Equivalents | 607.11M |
| Total Debt | 3.58B |
| Net Cash | -2.98B |
| Net Cash Per Share | -6.97 |
| Equity (Book Value) | 5.86B |
| Book Value Per Share | 13.71 |
| Working Capital | 502.83M |
Cash Flow
In the last 12 months, operating cash flow was 830.11 million and capital expenditures -137.95 million, giving a free cash flow of 692.16 million.
| Operating Cash Flow | 830.11M |
| Capital Expenditures | -137.95M |
| Depreciation & Amortization | 172.49M |
| Net Borrowing | -318.79M |
| Free Cash Flow | 692.16M |
| FCF Per Share | 1.62 |
Margins
Gross margin is 61.97%, with operating and profit margins of 13.09% and 8.94%.
| Gross Margin | 61.97% |
| Operating Margin | 13.09% |
| Pretax Margin | 11.61% |
| Profit Margin | 8.94% |
| EBITDA Margin | 15.92% |
| EBIT Margin | 13.09% |
| FCF Margin | 11.14% |
Dividends & Yields
Embla Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.42% |
| Shareholder Yield | 0.42% |
| Earnings Yield | 4.86% |
| FCF Yield | 6.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |